Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 4Gynecologic 4Sarcoma 3Head & Neck 3Genitourinary 3Dermatologic 3Breast 3Lymphoid 1Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 1307Carcinoma, Renal Cell 660Urinary Bladder Neoplasms 405Carcinoma, Non-Small-Cell Lung 333Neoplasms 301Carcinoma, Transitional Cell 263Breast Neoplasms 252Ovarian Neoplasms 248Melanoma 235Colorectal Neoplasms 227Neoplasm Metastasis 214Kidney Neoplasms 200Pancreatic Neoplasms 169Stomach Neoplasms 162Squamous Cell Carcinoma of Head and Neck 143Lung Neoplasms 140Uterine Cervical Neoplasms 123Non-Muscle Invasive Bladder Neoplasms 118Triple Negative Breast Neoplasms 112Head and Neck Neoplasms 111Endometrial Neoplasms 109Esophageal Neoplasms 107Carcinoma, Hepatocellular 97Small Cell Lung Carcinoma 80Sarcoma 75Colonic Neoplasms 55Urologic Neoplasms 53Prostatic Neoplasms, Castration-Resistant 47Liver Neoplasms 47Cholangiocarcinoma 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Vaccinia × Genitourinary × Clear all
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Vaccinia, Colorectal Neoplasms

NCT01169584 2016-01-21

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

SillaJen, Inc.

Phase 1 Completed
6 enrolled
CNSGenitourinaryLymphoidSarcoma

Lymphoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Vaccinia, Neurofibrosarcoma

NCT00625456 2015-12-03

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

SillaJen, Inc.

Phase 1 Completed
23 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡